Precision Medicine in Oncology®

Dr. Debu Tripathy from the USC Norris Cancer Center on Connecting Markers to Clinical Outcomes

Established in 1970 as a small clinic for cancer patients, the Georgetown Lombardi Comprehensive Cancer Center was named for football coach Vince Lombardi, who was treated for cancer at Georgetown University Hospital.

Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Biomarkers

Dr. Matthew J. Ellis from Washington University Discusses the Future of the PI3-Kinase Pathway

Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67

It's hard to tell which moves more quickly: Edith Perez's feet, or her mind.

Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials

Dr. Debu Tripathy from UC Norris Cancer Center Discusses HER2 Targeted Therapies

Biological markers that help clinicians choose which treatment options to pursue for particular patients are attracting increased research interest.

Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence

Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

Amid a continuing emphasis on targeted therapies, pharmaceutical companies have approximately 300 drugs in phase II or later-stage development for cancer treatment.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Available Targeted Therapies

As personalized medicine occupies a growing role in the pharmaceutical pipeline, major companies are changing their research and development paradigms.

The oncology community is quite conversant with the clinical utility of prognostic tumor markers.

In the context of caring for cancer patients, all physicians and nurses trained in oncology receive education in quality-of-life issues; however, prolonging quantity of life remains our ultimate goal.

Previously unknown genetic methylation patterns and new mutations for squamous cell carcinoma of the head and neck discovered.

PFS improved significantly in patients with EGFR-mutated advanced NSCLC treated first line with erlotinib versus platinum-based chemotherapy.

Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials

When Robert A. Weinberg was a boy, he loved dissecting what was complicated and figuring out what made it work.